Ashvattha’s technology platform consists of hydroxyl dendrimers that selectively target actively endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body. Quiescent macrophage and other non-endocytosing cells do not take up the hydroxyl dendrimer.
Selective Targeting and Improved Efficacy
Animal studies have shown that compounds conjugated to Ashvattha’s hydroxyl dendrimer are significantly more efficacious than free drug alone. The improved efficacy is due to the dendrimers ability to precisely target only actively endocytosing cells such as reactive macrophages and release the drug payload only within the cell and under desired kinetics established by the size of the dendrimer and corresponding linker chemistry.
In numerous studies, including clinical work in healthy subjects, compounds conjugated to Asvhattha’s hydroxyl dendrimers do not bind to serum or plasma proteins, exhibit no off target toxicity, and are excreted intact in the urine.